J&J's Tremfya shows sustained remission in Crohn's at 3 years

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. GOOGL
6. RTX
7. COF
8. SMCI
9. TSLA
10. BRZE

Go back to J&J's Tremfya shows sustained remission in Crohn's at 3 years

TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease

October 12, 2026 4:05 PM EDT

New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease 88% of patients achieved 90-day corticosteroid-free clinical remission

SPRING HOUSE, Pa., Oct. 12, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for... More